Researchers used spatial multi-omics to track how macrophage populations change across MASLD progression, pinpointing markers that may help stratify patients for clinical trials. The work focuses on tissue-context changes that bulk profiling can miss, and it ties macrophage subpopulations to disease stage in MASLD. By identifying shifting macrophage signatures along progression, the study provides a more granular set of candidate biomarkers for trial enrichment and patient selection. That could improve the odds of matching patients to therapies intended to modulate inflammation and liver immune cell dynamics.